- Home
- PRAX vs SIBN Comparison
PRAX vs SIBN Comparison
Compare PRAX & SIBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- SIBN
- Stock Information
- Founded
- PRAX 2015
- SIBN 2008
- Country
- PRAX United States
- SIBN United States
- Employees
- PRAX N/A
- SIBN N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- SIBN Medical/Dental Instruments
- Sector
- PRAX Health Care
- SIBN Health Care
- Exchange
- PRAX Nasdaq
- SIBN Nasdaq
- Market Cap
- PRAX 599.7M
- SIBN 567.6M
- IPO Year
- PRAX 2020
- SIBN 2018
- Fundamental
- Price
- PRAX $33.79
- SIBN $13.85
- Analyst Decision
- PRAX Strong Buy
- SIBN Strong Buy
- Analyst Count
- PRAX 9
- SIBN 5
- Target Price
- PRAX $123.33
- SIBN $24.40
- AVG Volume (30 Days)
- PRAX 570.3K
- SIBN 384.6K
- Earning Date
- PRAX 05-12-2025
- SIBN 05-05-2025
- Dividend Yield
- PRAX N/A
- SIBN N/A
- EPS Growth
- PRAX N/A
- SIBN N/A
- EPS
- PRAX N/A
- SIBN N/A
- Revenue
- PRAX $8,553,000.00
- SIBN $167,178,000.00
- Revenue This Year
- PRAX N/A
- SIBN $18.52
- Revenue Next Year
- PRAX $789.73
- SIBN $16.39
- P/E Ratio
- PRAX N/A
- SIBN N/A
- Revenue Growth
- PRAX 249.53
- SIBN 20.37
- 52 Week Low
- PRAX $26.70
- SIBN $11.70
- 52 Week High
- PRAX $91.83
- SIBN $19.16
- Technical
- Relative Strength Index (RSI)
- PRAX 43.73
- SIBN 45.88
- Support Level
- PRAX $28.79
- SIBN $12.87
- Resistance Level
- PRAX $30.88
- SIBN $13.74
- Average True Range (ATR)
- PRAX 3.07
- SIBN 0.87
- MACD
- PRAX 0.88
- SIBN 0.08
- Stochastic Oscillator
- PRAX 56.05
- SIBN 69.95
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About SIBN SI-BONE Inc.
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.